JP2024520751A5 - - Google Patents

Info

Publication number
JP2024520751A5
JP2024520751A5 JP2023575364A JP2023575364A JP2024520751A5 JP 2024520751 A5 JP2024520751 A5 JP 2024520751A5 JP 2023575364 A JP2023575364 A JP 2023575364A JP 2023575364 A JP2023575364 A JP 2023575364A JP 2024520751 A5 JP2024520751 A5 JP 2024520751A5
Authority
JP
Japan
Prior art keywords
disorder
salt
acid
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520751A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/072802 external-priority patent/WO2022261633A1/en
Publication of JP2024520751A publication Critical patent/JP2024520751A/ja
Publication of JP2024520751A5 publication Critical patent/JP2024520751A5/ja
Pending legal-status Critical Current

Links

JP2023575364A 2021-06-07 2022-06-07 新規塩および結晶 Pending JP2024520751A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163197848P 2021-06-07 2021-06-07
US63/197,848 2021-06-07
PCT/US2022/072802 WO2022261633A1 (en) 2021-06-07 2022-06-07 Novel salts and crystals

Publications (2)

Publication Number Publication Date
JP2024520751A JP2024520751A (ja) 2024-05-24
JP2024520751A5 true JP2024520751A5 (cg-RX-API-DMAC7.html) 2025-06-16

Family

ID=84425422

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575364A Pending JP2024520751A (ja) 2021-06-07 2022-06-07 新規塩および結晶

Country Status (10)

Country Link
US (1) US20240279228A1 (cg-RX-API-DMAC7.html)
EP (1) EP4352057A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520751A (cg-RX-API-DMAC7.html)
KR (1) KR20240018528A (cg-RX-API-DMAC7.html)
CN (1) CN117425652A (cg-RX-API-DMAC7.html)
AU (1) AU2022289909A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217549A1 (cg-RX-API-DMAC7.html)
IL (1) IL308750A (cg-RX-API-DMAC7.html)
MX (1) MX2023014398A (cg-RX-API-DMAC7.html)
WO (1) WO2022261633A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
ES3047409T3 (en) 2018-12-17 2025-12-03 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
US12331052B2 (en) 2018-12-21 2025-06-17 Intra-Cellular Therapies, Inc. Organic compounds
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530090T3 (es) * 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
RU2743513C2 (ru) * 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2017172811A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
EP3801527B1 (en) * 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
IL315005B2 (en) * 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
JP7377871B2 (ja) * 2018-12-21 2023-11-10 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物

Similar Documents

Publication Publication Date Title
EP4151277B1 (en) Substituted piperidine compound and application thereof
US20230357243A1 (en) Lsd derivatives, synthesis & method for treatment of diseases and disorders
JP2014062108A (ja) モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
NZ244616A (en) Mono-fluorinated derivatives of n-propargyl-1-aminoindan, preparation and pharmaceutical compositions thereof
JP2016510768A (ja) 抗不安化合物の塩、共結晶及び多形
WO2023130117A1 (en) Deuterated organic compounds and uses thereof
WO2025010259A2 (en) Deuterated organic compounds and uses thereof
CN103781771B (zh) 苯并噻唑酮化合物
CN104557568B (zh) 烟碱受体非竞争性拮抗剂
CN102340992B (zh) 吡咯烷三重再摄取抑制剂
AU2013221406B2 (en) Peripherally restricted diphenyl purine derivatives
KR20240134870A (ko) 치환된 피페리딘 화합물의 결정, 치환된 피페리딘 화합물의 염, 및 이의 결정
CN113784755B (zh) 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
US11396511B2 (en) Substituted 9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-ylbenzamides as anti-inflammatory and analgesic agents
JPWO2007126020A1 (ja) Nmda受容体チャネルブロック作用を示す化合物及びそれを用いた薬剤。
TW201136588A (en) Tropinone benzylamines as beta-tryptase inhibitors
JP7591592B2 (ja) 置換ピペリジン化合物を含有する医薬
CN104736525B (zh) 作为β-2肾上腺受体激动剂的苯并噻唑酮化合物的盐
CN118284607A (zh) 用于治疗疾病和障碍的lsd衍生物、合成和方法
TW201249841A (en) Novel salt forms of 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
KR20140098115A (ko) 니코틴 수용체 비-경쟁적 조절제
HK1144931A (en) Amino acid derivatives
HK1163451B (en) Pyrrolidine triple reuptake inhibitors
JP2011522016A (ja) 4−ブロモフェニル1,4−ジアザビシクロ[3.2.2]ノナン−4−カルボキシラートのフマル酸塩、この結晶形態、調製、および治療的使用